Study guide
Carcinogenesis, Immunology, and Cancer Biology
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Carcinogenesis, Immunology, and Cancer Biology
Key Takeaways Explain This Topic AI
Carcinogenesis is a multistep process (initiation, promotion, progression) in which clones accumulate mutations that confer growth and survival advantages.
Hanahan and Weinberg's hallmarks include sustained proliferation, evasion of apoptosis, angiogenesis, invasion and metastasis, immune evasion, and genomic instability.
The Oncology Certified Nurse (OCN) links symptoms, lab changes, and toxicities to disease mechanism, then escalates within registered nurse (RN) scope.
Checkpoint pathways (PD-1, PD-L1, CTLA-4) explain how immunotherapy works and why immune-related adverse events (irAEs) inflame normal organs.
On the OCN exam, the Oncology Nursing Society blueprint weights Treatment Modalities and Symptom Management heavily; biology questions test application, not memorization of pathways.
Last updated: June 2026
- Carcinogenesis, Immunology, and Cancer Biology
- Why This Matters for OCN Practice
The Oncology Certified Nurse (OCN) exam, administered by the Oncology Nursing Certification Corporation (ONCC), is a 165-item test (145 scored, 20 unscored pretest) delivered in a 3-hour PSI session; a scaled score of 55 (on a 25-75 scale) passes. Biology questions almost never ask you to recite a pathway. They embed biology inside a scenario: a lung-cancer patient with new confusion may have brain metastasis, hyponatremia from syndrome of inappropriate antidiuretic hormone (SIADH), hypercalcemia, infection, or hypoxia.
A checkpoint-inhibitor patient with diarrhea may have a routine virus, but the OCN must also weigh immune-mediated colitis and escalate early.
Carcinogenesis in Usable Terms
Carcinogenesis is the multistep transformation of normal cells into malignant ones. Initiation is irreversible DNA damage to a single cell. Promotion expands that altered clone, often through chronic inflammation, hormones, tobacco, ultraviolet (UV) light, or obesity. Progression adds further mutations that enable invasion, angiogenesis, and metastasis. The nurse does not diagnose the molecular event; the nurse uses the model to anchor prevention teaching and family-history collection.
Hallmarks and Nursing Assessment
- Cancer behavior Clinical meaning Nursing assessment link
- Uncontrolled proliferation Mass effect, marrow crowding New pain, cytopenias, obstruction, neurologic change
Angiogenesis Tumor recruits blood supply Bleeding, hemoptysis; anti-VEGF (vascular endothelial growth factor) bleeding/wound precautions
- Resisting apoptosis Cells survive that should die Treatment resistance, slow response
- Invasion and metastasis Spread via lymph, blood, body cavities Bone pain, dyspnea, ascites, neuro deficits
- Immune evasion Tumor hides from host defenses Rationale for checkpoint therapy and irAE monitoring
- Genomic instability Accumulating mutations Rationale for biomarker testing and clonal resistance
- Known Carcinogens and Viral Drivers
High-yield infectious and environmental links the OCN must teach: human papillomavirus (HPV) causes cervical, anal, vulvar, penile, and oropharyngeal cancers; hepatitis B and C virus drive hepatocellular carcinoma; Epstein-Barr virus (EBV) is tied to nasopharyngeal carcinoma and some lymphomas; Helicobacter pylori to gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma; and UV exposure to melanoma. Tobacco is linked to lung, head and neck, bladder, pancreatic, kidney, and cervical cancers. These associations drive teaching about HPV and hepatitis B vaccination, cessation, sun safety, and screening.
Tumor Immunology for the Bedside
The immune system performs immune surveillance , recognizing tumor antigens and destroying abnormal cells. Tumors escape by downregulating antigen presentation, recruiting suppressive regulatory T cells, secreting inhibitory cytokines, and exploiting immune checkpoints . Checkpoints are the brakes on T cells: when a tumor's PD-L1 ligand binds the T cell's PD-1 receptor, the T cell powers down. Checkpoint inhibitors (anti-PD-1 such as pembrolizumab and nivolumab; anti-PD-L1 such as atezolizumab; anti-CTLA-4 such as ipilimumab) release those brakes so T cells attack the tumor.
Releasing the brakes also lets immunity attack healthy tissue, producing immune-related adverse events (irAEs) that can hit any organ. The nurse monitors for and escalates the high-stakes patterns below. Severity is described with the Common Terminology Criteria for Adverse Events (CTCAE v5.0); for example, diarrhea is Grade 1 at fewer than 4 stools above baseline per day, Grade 2 at 4-6, and Grade 3 at 7 or more.
Colitis: watery diarrhea, cramping, blood or mucus — escalate before dehydration worsens.
Pneumonitis: new cough, dyspnea, falling oxygen saturation — potentially fatal.
Hepatitis: rising transaminases, jaundice, right-upper-quadrant pain.
Endocrinopathy: hypophysitis, thyroiditis, adrenal insufficiency, new diabetes — fatigue, headache, hypotension.
Myocarditis, nephritis, neuropathy, severe rash: rare but life-threatening.
Management principle the OCN must know: most moderate-to-severe irAEs are treated by holding the drug and giving corticosteroids , which differs sharply from chemotherapy toxicity. Anti-CTLA-4 agents and combination regimens cause more frequent and severe irAEs than single-agent PD-1 blockade.
Inflammation and Paraneoplastic Biology
Chronic inflammation both promotes carcinogenesis and produces systemic symptoms: tumor fever, cachexia, fatigue, anemia of inflammation, and hypercoagulability (cancer-associated venous thromboembolism). Paraneoplastic syndromes are remote effects of tumor-secreted substances — SIADH and Lambert-Eaton in small cell lung cancer, hypercalcemia of malignancy from parathyroid hormone-related protein, and Cushing syndrome from ectopic adrenocorticotropic hormone.
Cell-Cycle Biology and Why Chemotherapy Hits Healthy Tissue
A practical reason cancer biology matters at the bedside is the cell cycle : G1 (growth), S (DNA synthesis), G2 (preparation), and M (mitosis), with G0 as the resting phase. Many cytotoxic drugs are cell-cycle-specific: antimetabolites act in S phase, taxanes and vinca alkaloids in M phase, while alkylating agents act in any phase. Because chemotherapy targets rapidly dividing cells, it predictably damages the normal fast-dividing tissues — bone marrow (myelosuppression with the nadir typically around 7-14 days), gastrointestinal mucosa (mucositis, diarrhea), and hair follicles (alopecia).
The OCN uses this to time nadir teaching, anticipate the neutropenia window, and explain why hair loss occurs. Tumor growth fraction and doubling time also explain why some cancers respond quickly while slow-growing tumors resist cycle-specific agents.
RN Scope and Safety Boundaries
Within RN scope: accurate assessment, toxicity and adherence education, infection and emergency precautions, referral coordination, and urgent escalation. Nurses translate biology into plain language ("cancer cells collect changes that let them grow, survive, and hide from your immune system") but do not interpret sequencing as a diagnosis or promise response. Escalate immediately for new neurologic deficits, airway or spinal-cord-compression symptoms, superior vena cava (SVC) syndrome signs, sepsis, tumor lysis risk, severe irAEs, uncontrolled bleeding, or abrupt performance-status decline.
The OCN exam blueprint from the Oncology Nursing Society weights treatment modalities and symptom management most heavily, so biology appears chiefly as the reasoning that justifies a monitoring or escalation choice rather than as standalone recall.